Perry Yaron, Courcoulas Anita P, Fernando Hiran C, Buenaventura Percival O, McCaughan James S, Luketich James D
Division of Thoracic and Foregut Surgery, University of Pittsburgh Medical Center Health System, Pennsylvania 15213, USA.
JSLS. 2004 Jan-Mar;8(1):19-23.
Gastroesophageal reflux disease (GERD) is commonly associated with morbid obesity (MO). Antireflux surgery has a higher failure rate in MO and addresses only one of the comorbidities present. This paper reviews the results of laparoscopic Roux-en-Y gastric bypass (LRYGBP) performed for recalcitrant GERD in MO.
Patients with recalcitrant GERD and a body mass index (BMI)>35 undergoing LRYGBP were included. LRYGB included crural repair, creation of a small gastric pouch (30 mL), and intestinal bypass (150 to 180 cm). All patients were followed in clinic and by telephone.
From February 1999 to April 2001, 57 patients (51 F, 6 M) with a mean age of 43 (range, 22 to 67) and a median BMI of 43 underwent LRYGBP. Hiatal hernia or esophagitis, or both, were present in 48, Barrett's in 2. LRYGBP was possible in 52 patients; 5 required open conversion. The median hospital stay was 3 days. Complications included 1 leak, 1 pulmonary emboli, 2 reoperations for internal roux limb hernia, and 7 gastrojejunal strictures. At a mean follow-up of 18 months (range, 3 to 30), all patients report improvement or no symptoms of GERD and a mean weight loss of 40 kg (range, 16 to 70). Quality of life scores (SF-36) were above national norms for physical and mental components (median 55, norms=50). GERD-health related quality of life median score was <1 (scale, 0 to 45, 0=asymptomatic, 45=worse).
LRYGBP was effective for recalcitrant GERD in MO. LRYGBP also led to weight loss and improvement in other comorbidites. Surgeons with minimally invasive expertise should consider LRYGBP for treatment of GERD in the morbidly obese.
胃食管反流病(GERD)通常与病态肥胖(MO)相关。抗反流手术在病态肥胖患者中的失败率较高,且仅解决了存在的一种合并症。本文回顾了腹腔镜Roux-en-Y胃旁路术(LRYGBP)治疗病态肥胖患者顽固性GERD的结果。
纳入患有顽固性GERD且体重指数(BMI)>35并接受LRYGBP的患者。LRYGB包括裂孔修复、创建一个小胃囊(30 mL)和肠道旁路(150至180 cm)。所有患者均在门诊和通过电话进行随访。
从1999年2月至2001年4月,57例患者(51例女性,6例男性)接受了LRYGBP,平均年龄43岁(范围22至67岁),BMI中位数为43。48例患者存在食管裂孔疝或食管炎,或两者皆有,2例有巴雷特食管。52例患者可行LRYGBP;5例需要转为开腹手术。中位住院时间为3天。并发症包括1例渗漏、1例肺栓塞、2例因内Roux袢疝再次手术以及7例胃空肠狭窄。平均随访18个月(范围3至30个月)时,所有患者均报告GERD症状改善或无症状,平均体重减轻40 kg(范围16至70 kg)。生活质量评分(SF-36)在身体和精神方面均高于国家规范(中位数55,规范值 = 50)。GERD相关生活质量中位数评分<1(评分范围0至45,0 = 无症状,45 = 最差)。
LRYGBP对病态肥胖患者的顽固性GERD有效。LRYGBP还导致体重减轻并改善了其他合并症。具有微创专业知识的外科医生应考虑采用LRYGBP治疗病态肥胖患者的GERD。